Journal
EMBO MOLECULAR MEDICINE
Volume 13, Issue 9, Pages -Publisher
WILEY
DOI: 10.15252/emmm.202013193
Keywords
autophagy; fibroblast growth factor receptor 1; KRAS-mutant cancer; polo-like kinase 1; synthetic lethal vulnerability
Categories
Funding
- Swiss National Science Foundation (SNSF) [310030_192648]
- Swiss Cancer League/Swiss Cancer Research Foundation [KFS-4851-08-2019]
- Cancer League of the Canton of Bern
- China Scholarship Council
Ask authors/readers for more resources
By combining FGFR1 and PLK1 inhibitors, synergistic cytotoxicity can be achieved in KRAS-mutant tumors, inducing cell death. This treatment induces apoptosis by upregulating ROS and activating the JNK/p38 pathway, while enhancing sensitivity of tumor cells to inhibitors by inhibiting autophagy.
KRAS oncoprotein is commonly mutated in human cancer, but effective therapies specifically targeting KRAS-driven tumors remain elusive. Here, we show that combined treatment with fibroblast growth factor receptor 1 (FGFR1) and polo-like kinase 1 (PLK1) inhibitors evoke synergistic cytotoxicity in KRAS-mutant tumor models in vitro and in vivo. Pharmacological and genetic suppression of FGFR1 and PLK1 synergizes to enhance anti-proliferative effects and cell death in KRAS-mutant lung and pancreatic but not colon nor KRAS wild-type cancer cells. Mechanistically, co-targeting FGFR1 and PLK1 upregulates reactive oxygen species (ROS), leading to oxidative stress-activated c-Jun N-terminal kinase (JNK)/p38 pathway and E2F1-induced apoptosis. We further delineate that autophagy protects from PLK1/FGFR1 inhibitor cytotoxicity and that antagonizing the compensation mechanism by clinically approved chloroquine fully realizes the therapeutic potential of PLK1 and FGFR1 targeting therapy, producing potent and durable responses in KRAS-mutant patient-derived xenografts and a genetically engineered mouse model of Kras-induced lung adenocarcinoma. These results suggest a previously unappreciated role for FGFR1 and PLK1 in the surveillance of metabolic stress and demonstrate a synergistic drug combination for treating KRAS-mutant cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available